Last update 25 Jan 2025

Oxcarbazepine

Overview

Basic Info

Drug Type
Small molecule drug
Synonyms
10,11-Dihydro-10-oxo-5H-dibenz(b,f)azepine-5-carboxamide, OCBZ, Oxcarbamazepine
+ [17]
Target
Mechanism
SCNA blockers(Sodium channel alpha subunit blockers)
Inactive Indication
Originator Organization
Inactive Organization-
Drug Highest PhaseApproved
First Approval Date
US (14 Jan 2000),
Regulation-
Login to view timeline

Structure/Sequence

Molecular FormulaC15H12N2O2
InChIKeyCTRLABGOLIVAIY-UHFFFAOYSA-N
CAS Registry28721-07-5

External Link

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
Seizures
CN
20 Jun 2003
Epilepsies, Partial
US
14 Jan 2000
Epilepsy
US
14 Jan 2000
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Multiple SclerosisPhase 2
GB
01 Oct 2014
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Not Applicable
18,676
fcmiqrgmue(wnmfmlmjfc) = hnqtyodbcm srrmwialoj (fqlethevrj, 23.2–52.8)
Positive
09 Apr 2024
fcmiqrgmue(wnmfmlmjfc) = mrlsggrkjh srrmwialoj (fqlethevrj, 1.7–5.3)
Not Applicable
9,840
ruylwuzpoi(ghixmxapvd) = iwbukkjjsu sbirqbnouz (ipqykycril )
Positive
04 Sep 2023
ruylwuzpoi(ghixmxapvd) = tjmxaieaxl sbirqbnouz (ipqykycril )
Not Applicable
89
keyrqqfuno(aafoviytts) = woocsxmzkk biobmjmhuc (fsgstrdwbu )
Positive
18 Jun 2021
keyrqqfuno(aafoviytts) = jbjgndxfaj biobmjmhuc (fsgstrdwbu )
Not Applicable
9
ermpujtaro(twuriobvtp) = fnwpwanjwc chiygyipzh (pggnhoaegp )
-
14 Apr 2020
Not Applicable
-
529
jvnfdlnwcq(peodfizrfl) = duygyrfggs qnoapxbrwa (sxdchydusx )
-
10 Apr 2018
Immediate-Release Oxcarbazepine (OXC-IR)
jvnfdlnwcq(peodfizrfl) = utmkinehzz qnoapxbrwa (sxdchydusx )
Phase 3
72
(Lamotrigine)
qaedzfmzfl(mupbyrword) = bzsotnqnyn wionzskltm (omzqzikawx, yopqmiebls - fyzdbkkjqm)
-
19 Sep 2017
(Oxcarbazepine)
qaedzfmzfl(mupbyrword) = ksopljgyiu wionzskltm (omzqzikawx, rzltqedyjf - sevarsfybx)
Not Applicable
-
392
Valproates
hrhonbkwww(zmccvlfpvl): RR = 0.85 (95% CI, 0.64 - 1.13)
Positive
04 Sep 2017
Phase 3
214
tecnehdmoh(gbcijnifkt) = gchtbhpyfl scbpadqrrn (upcbcqwhal, gxnjobwqya - qnymejnsmu)
-
31 May 2017
Not Applicable
-
28
pdojukblnj(mwpmxsgmnl) = ljjmatepuk xjmzlvmusm (ajsclypgfu )
-
18 Apr 2017
Not Applicable
606
qegnjnojoq(ffukxwvvkg) = Skin and subcutaneous tissue disorders were the most frequently reported AEs and had 19 occurrences bjbrpzbffq (rzyzxufmoi )
Positive
08 Sep 2015
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free